SERENITY will be organised through 6 work packages over a five-year timescale

OUTPUT WP1: UNDERSTANDING CURRENT PRACTICE AND THE COMPLEXITY OF DECISION-MAKING IN END-OF-LIFE CARE

Flash mob study

The pre-registration for the flash mob study was closed after 467 pre-registrations.
The survey was launched on 4 July 2023 and closed on July 11 2023. The final numbers of completed surveys and partially completed surveys were 180 and 28, respectively

Achievements

Study initiation packages for epidemiological studies, including protocol with complete statistical plan.
Study initiation packages for realist review, including registration on PROSPERO.
Report on findings of the realist review on PROSPERO.

 

OUTPUT WP 2: Epidemiological studies

Achievements

Report on findings of the Danish study submitted.
Report on findings of the Dutch study submitted.

Early findings from the Realist Review

Poster presentation by Gazme Keser et al.
Towards cancer patient empowerment for optimal use of antithrombotic therapy at the end of life (SERENITY): A realist review of how deprescribing interventions can improve shared decision making for cancer patients in the last year of life.

 

Output WP3: Qualitative research

Achievements

Midterm recruitment report of qualitative studies submitted.
For Work Package 3 the first interviews have started.
The pre-registration for the Physician Survey has been opened.

Output WP4: Delphi process
Output WP5: Development and testing of the Shared Decision Support Tool
Output WP6: Cluster-randomized controlled trial

Publications

“Who am I to say that I’m not going to take it”: patient perspectives on decisions about antithrombotic therapy in the context of advanced cancer.
Elin Baddeley et al. Thromb Res. 2025 Sep:253:109399.
DOI: 10.1016/j.thromres.2025.109399. Epub 2025 Jul 6.
(WP 3 – patient perspective)

Anti-thrombotic therapy in patients with cancer at the end of life and associated clinical outcomes: A cohort study using population-linked routinely collected data
Sarah J. Aldridge et al. British Journal of Haematology. First published: 01 September 2025.
DOI.org/10.1111/bjh.70032
(WP2 – Welsh study); WP2 Utrecht study submitted; WP 2 Leiden study manuscript in preparation, results presented @ISTH; WP 2 combined paper predictors of adverse events in preparation, results presented @ISTH)

Shared decision-making and deprescribing to support anti-thrombotic therapy (dis)continuance for persons living with cancer in their last phase of life: A realist synthesis.
Justin Jagosh et al. PLoS Med. 2025 Aug 25;22(8):e1004663.
DOI: 10.1371/journal.pmed.1004663
(WP 1 – review)

Quality of vitamin K antagonist treatment during the last year of life.
Chantal Visser et al.
Hemasphere. 2025 May 19;9(5):e70135.
DOI: 10.1002/hem3.70135. eCollection 2025 May.
(WP 2 – Quality of vitamin K antagonist treatment)

Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease.
Eva K. Kempers et al. Thromb Haemost. 2025 Apr 4.
DOI: 10.1055/a-2524-5334. Online ahead of print.
(WP 2 – discontinuation of vitamin K antagonist treatment)

Understanding European patterns of deprescribing antithrombotic medication during end-of-life care in patients with cancer.
E.S.L. Martens et al., Thromb Res. 2025 Jan:245:109205.
DOI: 10.1016/j.thromres.2024.109205. Epub 2024 Nov 9.
(WP 1 – flash mob)

Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study.
Mette Søgaard et al. J Thromb Haemost. 2025 Jan;23(1):190-200.
DOI: 10.1016/j.jtha.2024.09.023. Epub 2024 Oct 10.
(WP 2 – Danish study)

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool.
Goedegebuur J et al. Thromb Res. 2023 Aug: 228:54-60.
DOI: 10.1016/j.thromres.2023.05.008

Upcoming Consortium Meetings

 

Past Consortium Meetings

02-04-2024, 19-04-2024, 27-09-2024, 27-01-2023, 21-04-2023, 01-09-2023

Timeline serenity project (duration 60 months)

month 0

month 60

  • FAIR data management and stewardship
  • Phase 1 | WP1: Realist review and Flash mob study
  • Phase 1 | WP2: Epidemiologic studies
  • Phase 1 | WP3: Qualitative studies
  • Phase 2 | WP4: Delphi
  • Phase 2 | WP5: Tool development, design and testing
  • Phase 3 | WP6: RCT
  • Phase 3 | WP7: Dissemination
  • WP8: Project Management
  • Public engagement